Pfizer-Valneva Lyme vaccine shows 70% efficacy in large trial
Pfizer and Valneva report that their four-dose experimental Lyme disease vaccine reduced infections by more than 70% in a 9,400-person trial and plan to seek regulatory approval, potentially becoming the first widely available Lyme vaccine; a previous vaccine, LYMErix, drew controversy despite no proven harm.